Literature DB >> 509414

Potentiation of antitumor effect of cyclophosphamide and hydrazine sulfate by treatment with the antidiabetic agent, 1-phenylethylbiguanide (phenformin).

V M Dilman, V N Anisimov.   

Abstract

It was shown that 1-phenylethylbiguanide (phenformin) administered orally to mice at a dose of 2 mg/day potentiated the antitumor effect of cyclophosphamide on transplantable squamous cell cervical carcinoma, hepatoma-22a and Lewis lung tumor, but did not alter the effect of cyclophosphamide on sarcoma-180 and L-1210. Oral administration of phenformin (5 mg/day) to rats with transplanted Walker 256 carcinoma enhanced the antitumor effect of hydrazine sulfate.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 509414     DOI： 10.1016/s0304-3835(79)80066-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  8 in total

Review 1.  Do metformin a real anticarcinogen? A critical reappraisal of experimental data.

Authors:  Vladimir N Anisimov
Journal:  Ann Transl Med       Date:  2014-06

2.  Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.

Authors:  David A Iglesias; Melinda S Yates; Dharini van der Hoeven; Travis L Rodkey; Qian Zhang; Ngai Na Co; Jennifer Burzawa; Sravanthi Chigurupati; Joseph Celestino; Jessica Bowser; Russell Broaddus; John F Hancock; Rosemarie Schmandt; Karen H Lu
Journal:  Mol Cancer Ther       Date:  2013-09-27       Impact factor: 6.261

3.  Compound C prevents the unfolded protein response during glucose deprivation through a mechanism independent of AMPK and BMP signaling.

Authors:  Sakae Saito; Aki Furuno; Junko Sakurai; Hae-Ryong Park; Kazuo Shin-ya; Akihiro Tomida
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

4.  Phenformin as prophylaxis and therapy in breast cancer xenografts.

Authors:  M V C L Appleyard; K E Murray; P J Coates; S Wullschleger; S E Bray; N M Kernohan; S Fleming; D R Alessi; A M Thompson
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

5.  Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.

Authors:  Jichang Wang; Guangyue Li; Yaochun Wang; Shouching Tang; Xin Sun; Xuefei Feng; Yan Li; Gang Bao; Pingping Li; Xiaona Mao; Maode Wang; Peijun Liu
Journal:  Oncotarget       Date:  2015-12-29

6.  Synthesis, Characterization, and Anticancer Activity of New Metal Complexes Derived from 2-Hydroxy-3-(hydroxyimino)-4-oxopentan-2-ylidene)benzohydrazide.

Authors:  Abdou Saad El-Tabl; Moshira Mohamed Abd El-Waheed; Mohammed Ahmed Wahba; Nahla Abd El-Halim Abou El-Fadl
Journal:  Bioinorg Chem Appl       Date:  2015-06-25       Impact factor: 7.778

7.  Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway.

Authors:  Zhiying Guo; Ming Zhao; Erin W Howard; Qingxia Zhao; Amanda B Parris; Zhikun Ma; Xiaohe Yang
Journal:  Oncotarget       Date:  2017-07-22

8.  Suppression of hypoxia-induced excessive angiogenesis by metformin via elevating tumor blood perfusion.

Authors:  Ji-Chang Wang; Guang-Yue Li; Ping-Ping Li; Xin Sun; Wei-Ming Li; Yan Li; Shao-Ying Lu; Pei-Jun Liu
Journal:  Oncotarget       Date:  2017-05-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.